OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:42 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

NCT03871829 · Janssen Research & Development, LLC · PHASE2 · terminated · last registry update 2025-03-30 · Multiple myeloma · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.”Open Targets' class: another study, negativeRegistry record, Janssen Research & Development, LLC

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PSMD1 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision